The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | The stratification of CLL patients and implications for clinical practice
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy talks about the stratification of chronic lymphocytic leukemia (CLL) patients at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. As the biology of CLL is better understood, this allows for the better stratification of CLL patients. Dr Ghia mentions how patients can be stratified based on the presence or absence of a 17p deletion and p53 gene mutation. According to Dr Ghia, the way patients are stratified will probably remain the same in the next couple of years despite the development of new therapies. He also discusses how with the new therapies, the age and fitness of patients will become less important.
